UCB names next chief executive
pharmafile | February 25, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | UCB, tellier
Biopharma firm UCB has confirmed its current chief executive Roch Doliveux is to be replaced by Jean-Christophe Tellier.
Tellier (pictured) who is currently the firm’s executive VP of Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee from March this year.
Doliveux still remains chief executive of UCB until next year, but as 2015 begins Tellier will take over this role indefinitely.
Gerhard Mayr, chairman of UCB’s board of directors, said: “We are confident that Jean-Christophe Tellier will continue to drive UCB to provide superior and sustainable value for patients. He and Roch will continue to work together throughout 2014 to ensure a smooth handover before Jean-Christophe takes the helm of UCB as of 1 January, 2015.”
Doliveux added that Tellier’s 25-year career in the biopharma industry, his patient-centric approach, his medical background as a rheumatologist and his passion for developing talent make him the perfect candidate to lead the company through its next phase.
“We are fortunate to have found UCB’s future leader internally; it has been a privilege for me to work with the board to identify and develop my successor,” he said.
Related Content
FDA accepts UCB’s sBLA for Bimzelx
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review …
Microsoft and UCB collaborate to treat immunological and neurological diseases
UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining …
UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
UCB Pharma is set to partner up with Roche and Genentech in a development and …